Herbal medicines put into context
Using herbal
medicines entails risks, but probably fewer than with synthetic drugs,
argues Erzard
Ernst

STEVE
HORREL/SPL
Patients worldwide have adopted
herbal medicine
Recent
reviews have rightly alerted us to the risk associated with herbal
medicines.1
This is necessary and important. But the more important question
probably is-do the risks of herbal benefits outweigh their
potential for harm? Therefore I will try to put herbal medicines into
context and consider the benefit they might
bring.
The potential benefits of
herbal medicines could lie in their high acceptance by patients,
efficacy, relative safety, and relatively low costs. Patients worldwide
seem to have adopted herbal medicines in a major way. Survey data from
the United Kingdom show that herbal medicine has been tried by about
30% of the British
population.2
The associated out of pocket expenditure was estimated to amount to
£31m (US$47.7m; €45m) in the United
Kingdom2
and £1300m in
Germany.3
Herbal medicines are used predominantly for minor and self limiting
indications, with respiratory tract infections heading the
list.3
But even for those conditions the remarkable acceptance of herbal
medicines can be a good thing only if they can be shown to do more good
than harm at reasonable cost.
The
efficacy of herbal medicines has been tested in hundreds of clinical
trials, and it is wrong to say that they are all of inferior
methodological quality. But this volume of data is still small
considering the multitude of herbal medicines-worldwide several
thousand different plants are being used for medicinal
purposes.4
A recent overview included 23 systematic reviews of rigorous trials of
herbal
medicines.5
Eleven came to a positive conclusion, nine yielded promising but not
convincing results, and three were negative. The relative paucity of
rigorous clinical trials is mostly due to the fact that, compared with
the pharmaceutical sector, the herbal industry is small and can rarely
afford the considerable expense of a clinical trial. Sadly the
traditional use directive, which sets out to harmonise the registration
of herbal medicines in the European
Union,6
lacks any incentive for companies to invest further into research.
Public funds are only very rarely dedicated to research in this
area.7

ERIKA CRADDOCK/SPL
Herbal medicine appeals to many
patients
Even though herbal medicines are not devoid of
risk,1
they could still be safer than synthetic drugs. Between 1968 and 1997,
the World Health Organization's monitoring centre collected 8985
reports of adverse events associated with herbal medicines from 55
countries.8
Although this number may seem impressively high, it amounts to only a
tiny fraction of adverse events associated with conventional drugs held
in the same
database.8
However, the relative paucity could also be due to a relatively higher
level of under-reporting. More conclusive evidence on the relative
risks of herbal medicine versus synthetic drugs is scarce. Linde et al
showed that the herbal antidepressant St John's wort has only
about half the rate of adverse effects compared with conventional
antidepressants.9
Kava, an effective herbal
anxiolytic,10
has recently been banned in several countries, including the United
Kingdom, because of the suspicion that, in rare cases, it causes
hepatotoxicity. None the less, preliminary data indicate that it
probably is still safer than
benzodiazepines.11
At present the relative safety of herbal medicines is undefinable, but
many of the existing data indicate that adverse events, particularly
serious ones, occur less often than with prescription
drugs.4
A
further strength of herbal medicines is that they are inexpensive, at
least this is what the "herbal lobby" wants us to believe.
The truth, however, is that almost no conclusive cost evaluation
studies are
available.12
Many, but by no means all, herbal medicines are inexpensive to buy; the
potential for cost savings by using more herbal medicines could
therefore be substantial-at present, however, we simply cannot be
sure.
Thus the evidence on herbal
medicines is incomplete, complex, and confusing. They are certainly
associated with both risks and
benefits.1
As more and more people try herbal medicines, the pressure increases on
healthcare professionals to be well informed about the subject, and on
researchers to fill the many and somewhat embarrassing gaps in our
current knowledge. Failing to do (and fund) this work would, in my
view, constitute the true risk associated with herbal
medicines.
Erzard Ernst, director Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, Exeter EX2 4NT
Email: Edzard.Ernst@pms.ac.uk
Competing interests: EE's unit has received research fellowships from herbal manufacturers and retailers: Lichtwer UK, Pharmaton Switzerland, and Boots UK. Financial support for other research projects was also received from Schwabe Germany and Novogen Australia.
studentBMJ 2004;12:1-44 February ISSN 0966-6494
- Corns CM. Herbal remedies and clinical biochemistry. Ann Clin Biochem 2003;40:489-507.
- Thomas KS, Nicoll JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001;9:2-11.
- Marstedt G, Moebius S. Inanspruchnahme alternativer Methoden in der Medizin: Gesundheitsberichtserstattung des Bunds 2000;9:1-37. (In German.)
- Ernst E, Pittler MH, Stevinson C, White AR, Eisenberg D. The desktop guide to complementary and alternative medicine. Edinburgh: Mosby 2001.
- Ernst E. Herbal medicinal products: an overview of systematic reviews and meta-analyses. Perfusion 2001;14:398-404.
- Barnes J. Quality and safety at heart of new herbals directive. Pharm J 2003;270:201-2.
- Ernst E, Wider B. Medical research charities should fund more trials. BMJ 2002;325:1245.
- Farah MH, Edwards R. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Safety 2000;9: 105-12.
- Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammeer W, Melchart D. St John's wort for depression-an overview and
meta-analysis of randomised clinical trials. BMJ 1996;313: 253-8.
- Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev
2003;(1):CD003383.
- Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions-a case study. Phytomedicine 2003;10(suppl 4):S68-73.
- White AR, Ernst E. Economic analysis of complementary medicine a systematic review. Complement Ther Med2000;8:111-8.